Low-Dose DOACs Reduce VTE Risk in Transplant-Ineligible Multiple Myeloma: Insights from the BENEFIT Trial
Journal of Thrombosis and Haemostasis (JTH) has shared a post on LinkedIn:
“Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of the BENEFIT trial
In this phase 3 trial of 257 patients with transplant-ineligible newly diagnosed multiple myeloma, the 6-month cumulative incidence of VTE was 4.8%. Among prophylaxis strategies, low-dose DOACs significantly reduced VTE risk compared to heparin or aspirin. Proteinuria ≥0.44 g/L and monoclonal protein ≥22 g/L emerged as strong independent risk factors for VTE. Findings highlight DOACs as a potentially superior prophylaxis option in this high-risk population.”
Title: Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Authors: Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, Thomas Lecompte, Bernard Tardy, Ilhame Bounouara, Manon Sapet, Arthur Bobin, Stephanie Harel, Olivier Decaux, Karim Belhadj, Cyrille Touzeau, Margaret Macro, Mohamad Mohty, Philippe Moreau, Jill Corre, Hervé Avet–Loiseau, Lionel Karlin, Thierry Facon, Aurore Perrot, Cyrille Hulin, Salomon Manier, Laurent Frenzel, Xavier Leleu
Read the full paper here.
Find similar posts on Hemostasis Today.
-
Oct 17, 2025, 08:37Salome Mekhuzla Invites You to Join WHO Essential Medicines List 2025 Updates Webinar on Hemophilia and VWD
-
Oct 17, 2025, 08:36Plasma Protein Forum 2025: From Anti-D Plasma and Blood Supply Incentives to the Future of AI
-
Oct 17, 2025, 08:33Hossam El Benawi to Present Latest Mayo Clinic Insights on Left Ventricular Thrombus at AHA 2026
-
Oct 17, 2025, 08:32Brian O Mahony Invites You to Irish Haemophilia Society Webinar Series
-
Oct 17, 2025, 08:30Thomas Reiser Invites You to Take A Survey on AI and Machine Learning From ISTH
-
Oct 17, 2025, 14:16Maxime Dely - CPD: The Silent Guardian of Our Blood Bags
-
Oct 17, 2025, 09:00Shreya Agarwal: We Describe Patients With PLG Mutations Who Experienced Recurrent TMA
-
Oct 17, 2025, 08:41Review of Community-Based Stroke Rehabilitation in LMICs from Dominique Cadilhac's Team
-
Oct 17, 2025, 06:40Multiple Retinal Artery Occlusions on Anticoagulation - What’s Next?
-
Oct 17, 2025, 06:39Emilia Arturo: Give Your Hematology Paper a Second Chance
-
Oct 16, 2025, 06:07ClearPlasma - A New Breakthrough in Stopping Life-Threatening Bleeds
-
Oct 14, 2025, 05:26Ryan C. Heniford: Every Thrombus Prevented Is a Patient Protected
-
Oct 13, 2025, 04:48Archil Jaliashvili showcases how BHOC builds on Hemopure’s success to revolutionize surgery and care
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 17, 2025, 16:07WFH Volunteer Mary Byrne Transforms Bleeding Disorder Diagnostics
-
Oct 17, 2025, 08:52Erica Sparkenbaugh: Shout Out to My Doctoral Student Kylie Hutchison for Her Outstanding Oral Presentation
-
Oct 17, 2025, 08:45Shamee Shastry Shares Lean and Six Sigma in Transfusion Medicine Training Program's Success
-
Oct 17, 2025, 06:26Kriti Batni: What a Privilege It is to Be Overwhelmed by The Life You Once Prayed For
-
Oct 16, 2025, 06:19Hanneke Takkenberg: Transforming Aneurysm Care — Together!